Mr John C Watkinson:
John Watkinson has a large UK thyroid clinical and research practice. Mr Watkinson has an MSc in Nuclear Medicine and MS in Surgery. He is an elected member (by thesis) of the American Triological Society, as well as the American Head & Neck Society. He held visiting professorships at both the Johns Hopkins Hospital in Baltimore, as well as Duke in Carolina, USA.He has published on all aspects of Head and Neck surgery. Mr Watkinson has over 300 publications and numerous book chapters in all the world’s leading textbooks on head & neck and thyroid disorders.
He was President of the British Association of Head and Neck Oncologists (BAHNO; 2009-2011), as well as President of British Association of Endocrine and Thyroid Surgeons (BAETS; 2011-2013), and was the first ENT surgeon to hold that honour. He is Chair of the Semon Committee (UCL) and President of the Royal Society of Medicine (RSM) Laryngology Section (2014-2015). He has been involved in a number of National guidelines including NICE, BTA, BAHNO, DAHNO and ENT-UK, and was awarded a Hunterian Professorship in 2009 from The Royal College of Surgeons of England.
London Thyroid Surgeons
He has organised and led the highly successful and influential Birmingham Head and Neck course for 10 years (1997-2006) and is currently the Chief Editor of Stell and Maran International and award-winning Textbook in Head & Neck Surgery. He has given a number of eponymous lectures, which include the Stell memorial lecture (2005), John Palmer (Toronto 2007), the Leegard lecture (2009), Hunterian (2009), the Wilde Discourse (2011) and RSM Presidential Address (2014).
In 1994, together with Adrian Drake-Lee, Dr Hilary Jones, the late Roy Castle and
Peter Scudamore he co-founded The Get A-Head Charitable Trust (www.getahead.org.uk). Through this charity he has helped to raise more than £6 Million pounds to support over 40 research projects of which half were Doctorate degrees (MD/PhD). He continues to support one of his past –trainees (Prof Kim) and together continues active research into the scientific basis of thyroid cancer. Currently they are studying the potential role of treating advanced cancers using new experimental immunotherapy agents within the Targeted Therapy Group under Prof Harrington at the Institute of Cancer Research, London